Activist fund swoops on EndoBarrier/GI Dynamics, page-2

First 2 Last

Share
Profile

Follow
Chanzformerz

1,089 Posts.

14/02/17

20:58

Post #: 22613204
Share

Originally posted by cadence1 ↑

As shares in $GID/GI Dynamics climb from the floor to a 52 week high, $HHL/Hunter Hall appears to have sold its second-ranking stake.

But did HHL sell because it's disillusioned with $GID or did it sell because of changes to top HHL management and portfolio policy settings as it fields a couple of takeover bids?
The group appears to have sealed a deal with Guernsey-registered Crystal Amber Fund run by UK activist managers Richard Bernstein and Jonathan Marsh.

CAFL paid Hunter Hall $2.3m for 92.5m shares. It hoisted its $GID stake from 22.65% to a lofty 38.73%.

While the opportunistic fund has larger investments in its portfolio, I suspect in percentage terms it has no higher commitment to a single stock than it now has to GID.

The GID purchase decision was important enough for the fund's Board to issue a press release.

The AIM-traded fund notes that GI Dynamics is the developer of EndoBarrier, the first minimally invasive device therapy approved for the treatment of type 2 diabetes and obesity.

EndoBarrier is a temporary bypass sleeve that is endoscopically delivered to the duodenal intestine, offering similar effects to the surgical gastric bypass, Crystal's Board says.

It is CE mark-approved and commercially available in Europe and a number of countries outside of the United States.

"The fund supports the current management's strategy to commercialise the device in Europe, initiate a new FDA trial and continue to gather clinical data.

"This would build on 2016's successes, including the 300 patient UK trials led by the Association of British Clinical Diabetologists and the data announced from the German registry, which included 243 patients.

"The company has achieved partial reimbursement in Germany and Israel and has received preliminary reimbursement codes in Holland and Switzerland."

Crystal Amber Directors conclude that GID has a world class technology, addressing an unmet clinical need, with its current share price a function of "shareholder disillusionment" resulting from past management disappointments.

Expand

agree and agree.

also to add. I did a past 1 yr returns analysis for crystal ambers "activist" strategy and some of the stocks have performed really well. One of them up over 500% since 10 Feb last year.

They wouldnt waste their time for nothing here. I believe they are of the view they will be able to unlock value from GID.

Will hold until further news.

GID Price at posting: 3.5¢ Sentiment: Hold Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

IMU

Imugene kicks off Australian trial for blood cancer treatment

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

Trump is President Again: What Does This Mean for Crypto?

UBI

Universal Biosensors flat despite fresh deal with US medical product distributor

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Week 45 Wrap: Combat sports usher in Trump 2.0 – or is it male insecurity?; RBA boring; Propane suggests China alive

Trump Victory Sends Bitcoin Surging Above $75K – Is $100K Next?

HotCopper Highlights: Your most watched and most discussed stocks this week

FG1

Flynn Gold reaches milestone exploration target for Golden Ridge

MMI

Metro Mining inks bauxite offtake contracts into 2026 with Chinese m